1. Introduction {#s0005}
===============

Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by the protozoan parasite, *Plasmodium*. According to WHO 2015 statistics, 212 million clinical episodes and 429,000 deaths were reported worldwide ([@b0015]); [@b0385]; [@b0185]; [@b0390]) and nearly 3.2 billion people are at the risk of malaria, especially children under age of 5 years, pregnant women, immune compromised patients, as well as non-immune migrants ([@b0320]; [@b0260]; [@b0360]). These large numbers are mainly subjected by *Plasmodium falciparum* (*P. falciparum*), followed by *P. vivax*, *P. ovale*, *P. malariae*, and to some extent *P. knowlesi*. Although in recent years, some profound development has been seen in antimalarial drug discovery, but higher number of resistance cases, mild to moderate selectivity/toxicity ratio of most of the antimalarial drugs, show a need of new scaffolds or new chemical entity (NCE) ([@b0035]). Moreover, the alkaloid natural product class has been found promising and useful in numerous disease states, as mentioned in these reports ([@b0190]; [@b0130]; [@b0290]; [@b0330]; [@b0325]). Additionally, alkaloids, such as Quinine, Cryptolepine, Thiaplakortones A--D and their semi or synthetic derivatives ([@b0040]; [@b0275]) are well studied as antimalarial agents ([@b0070]; [@b0090]), showing alkaloidal scaffold inheritance of antiplasmodial activity.

In recent years, various medicinal active natural compounds were reported from a plant, *Cassia siamea* (Leguminosae). Most of these natural compounds are either isolated from leaves (Cassiarin-A, B, G, H, J, K, 5-acetonyl-7-hydroxy-2-methylchromene, Chrobisiamone A) ([@b0240]; [@b0285]; [@b0095]), or flower (Cassiarin C, D, E, F; 10,11-dihydroanhydrobarakol, anhydrobarakol Cassibiphenol A and Cassibiphenol B) ([@b9005]) ([@b0105]), or also from twigs (Siamalkaloids A, B, C) ([@b0395]), structures shown in [Fig. 1](#f0005){ref-type="fig"}. Surprisingly, Cassiarin-A and Cassiarin-B were found highly selective than Chloroquine against chloroquine sensitive *P. falciparum* 3D7 strain over human breast cancer cell lines (MCF7), as selectivity/cytotoxicity ratio are fairly high, ≥4348, ≥1112, 3281 for Cassiarin-A, B and Chloroquine, respectively ([@b0245]). Furthermore, their antimalarial role was purposed though their vasorelaxation activity, as prompted by nitric oxide production from the endothelium, which might inhibit the host cell surface attachment of the parasite ([@b0245]). In 2009, Oshimi et al. isolated Cassiarins C-E and 10,11-dihydroanhydrobarakol which showed reasonable *in vitro* selectivity against *P. falciparum* 3D7 over human leukaemia cells (HL-60 cell lines) ([@b0280]).Fig. 1Chemical structures of compounds isolated from *Cassia siamea* (Leguminosae).

1.1. Chemistry {#s0010}
--------------

Isoquinoline is the basic alkaloidal core of Cassiarins, which fused with 2-methyl-2*H*-pyran ring at position \[4, 8a\], forms tricyclic ring and as prototype represented in the structure Cassiarin-C (shown in [Fig. 1](#f0005){ref-type="fig"}). Further derivatization at *C~2~* position of Cassiarin-C, forms Cassiarin D, E and F. The methyl at *C*~2~ in the pyran ring of these isoforms (Cassiarin-C, D and E), can adopt 2 conformations as *R* or *S*. Every isoform has its own structure signature at *C*~2~ position, when compare to Cassiarin-C structure, which has simply a methyl group: (a) Cassiarin-D has --CH~2~-- tethered 5-propenone-7-hydroxy-4*H*-chromen-4-one functionality at *C*~2~ with regards to Cassiarin-C, as shown in [Fig. 1](#f0005){ref-type="fig"}; (c) Cassiarin E is *Bis*-isomer of Cassiarin-C; (d) Cassiarin-F has fused with a toluene ring, to form a tetracyclic ring at position \[2,3\] of Cassiarin-C and also has further substructure extension in a form of 2-resorcinol propanone functionality, shown in [Fig. 1](#f0005){ref-type="fig"}.

In order, to characterize the molecular targets for these Cassiarin alkaloids, we used inverse docking, which is grown as a valuable tool in drug target identification in recent years. Also, helpful in rediscovering the molecular mechanism of polypharmacological active compounds, especially, the natural products and detecting, the possible adverse side targets of existing drugs as in toxicological studies. Previous reports on inverse docking shows implementation of various methodologies, to improve the accuracy and prioritizing the identified targets. Kumar et al. tried to address the limitations of docking scoring schemes with respect to attain confidence in theoretical binding affinities ([@b0210]). They presented a reverse approach, where they used the pharmacophore features of the ligand as interactions of complementary amino acids of protein cavities (also, called them as "pseudoreceptor"). These pseudoreceptors were then matched with the cavities/ binding sites of the selected protein dataset. They applied this approach on 3 co-crystallized ligands over 28 proteins of Zea mays and provide an application of the total probability and docking energy, in order to acquire confidence in prioritizing the probable protein targets ([@b0210]). Also, Carvalho et al. adopted a reverse screening strategy based on ligand similarity and target structure, which resulted into, a number of putative protein target candidates for quercetin polypharmacological effects and also successfully correlated them, with previously tested proteins, mainly protein kinases and poly \[ADP-ribose\] polymerases ([@b0045]). In another report, Kumar et al. compared the rank list results from inverse docking and ligand-based similarity search, assist them to prioritize the chitinase as most probable target for kinetin molecule, further supported by experimental data ([@b0215]). While, few compiled literature reviews on inverse screening and its application are available, related to the drug repositioning ([@b0195]) and available target databases/servers ([@b0225]).

However, the selectivity/cytotoxicity profile of these reported Cassiarin alkaloids has been promising in *P. falciparum* but as their protein targets are poorly recognised, which certainly limits their further exploration as antimalarial candidature. To identify their protein targets and acquire significant confidence in prioritising the identified target, we used reverse screening on all available protein targets from protein data bank, using three different placement docking methods.

2. Materials & methods {#s0015}
======================

2.1. Proteins set {#s0020}
-----------------

All the protein targets for *P. falciparum* were searched on protein data bank, claiming 1047 structures. After filtering off the NMR and low resolved cryo-electron structures from X-ray structures, proteins were selected and arranged in the order of their crystal structure resolution as an individual target, see in [Table 2](#t0010){ref-type="table"}. In most cases, preferences were given to co-crystallised ligand containing protein structures, otherwise the structures without co-crystallised ligand protein were also selected. Later, the self-docking on co-crystallise ligand containing protein targets, was performed to calculate the minimum RMSD values (min. RMSD values) in order, to evaluate the competency of a particular protein in accommodating of its own co-crystallise ligand (also, called ligandability) ([@b0205]). In those structures, which lack co-crystallise ligand, active site finder tool of MOE ([@b0110]; [@b0265], [@b0260]) was used to find the active surface patches which were saved as dummy atoms for performing the later docking. Also, in certain cases we aligned the target protein sequences with their homologous proteins of other species. These studies involved superposition of three-dimensional structure of the proteins of interest, as to see the overlapped domains and regions with comparative homologous proteins, which could be inferred into key active site residues in those proteins which were poorly studied in the past.

2.2. Ligand set {#s0025}
---------------

As absolute stereochemistry at *C*~2~ position of Cassiarins is unknown, therefore we build both (*R*) and (*S*) stereoisomers, which were further minimised by MMFF94x Forcefield. Although, the energy minimisation step showed a reasonable energy difference between both the stereoisomer forms of individual Cassiarins (C, D, E & DBH), but these were used as such in our molecular modelling studies, as to avoid any pseudo positive or misleading results.

2.3. Molecular modelling {#s0030}
------------------------

The proteins were prepared by, (a) removing of the water molecules from their crystal structures; (b) modelling the missing or breaks in their loops; and (c) protonation of the structure. Later, the co-crystallise ligand binding site or saved dummy atoms on proteins were used for docking of the Cassiarins. This inverse screening was performed by utilising 2 docking placement methods (also called, "Differential placement method based docking"). The first was the alpha triangle placement method, which generates the ligand-protein poses based on the overlapping of ligand atom triplets onto the triplets of protein point sites (are, also called alpha sphere centres). At each iteration cycle, a pose was determine based on sampling of a random triplet of ligand atoms over a random triplet of alpha sphere centres. The following setting was used for this method: minimum and maximum iterations cycles were set 800,000 and 5,000,000 respectively with timeout (6000 s). The second was triangle matcher placement method, which generate the ligand-protein poses by aligning the ligand atoms triplet on triplets of alpha spheres in a more systematic way than in the Alpha Triangle method (method setting was, total number of returned poses was set 100,000, with time out 3000 s). Lastly, we utilised another approach which was different than the previous docking methods, i.e. grid based docking, as a part of VlifeMDS suite tool ([@b0350]) which uses the genetic algorithm for grid formation and docking. Later, we compare the docking binding affinities, resulted from these methods, to get the confidence in prioritising the most putative Cassiarin targets.

3. Result and discussions {#s0035}
=========================

3.1. Protein set and docking {#s0040}
----------------------------

All the 1047 proteins were retrieved from protein data bank, which were found to belongs to 147 different protein-types. This protein dataset was divided into 2 categorises: one which has co-crystallise ligands and other one, without co-crystallise ligands. In case of co-crystallise ligand containing protein-types, we considered all those structures for a protein where co-crystallise ligand has a diverse chemotype in its structure. Later, we performed the self-docking to filter the most suitable protein crystal structure based on the min. RMSD value for its own co-crystallise ligand. In those protein-type, where protein structure does not contain any co-crystallise ligand, the structures were chosen based on their resolution (*Res.*). In order, to find the active site on those structure which does not contain co-crystallise ligand, active site finder tool was used to identify the active patches for the docking. Later, alpha triangle and triangle matcher placement methods resulted in various docking poses, which were ranked by GBVI/WSA *dG* scoring function (results for alpha triangle and triangle matcher are provided in [Supplementary information](#s0140){ref-type="sec"}, [Table 1](#t0005){ref-type="table"} and [Table 2](#t0010){ref-type="table"} respectively). While, the grid based docking results are enlisted in [Supplementary information](#s0140){ref-type="sec"} as [Table 3](#t0015){ref-type="table"}. The grid based docking was performed on a larger area (80 × 80 × 80), as increased size of sheared active cavity results more conspicuous differences in the docking energies which could be useful in separating closely related putative targets.Table 1Enlisting the *in vitro* antiplasmodial and cytotoxicity activities of natural compounds isolated from *Cassia siamea* plant.AlkaloidsPlasmodium facliparum (IC50 = µM)Cytotoxicity (µM)ReferenceChloroquine0.011[a](#tblfn1){ref-type="table-fn"}36.1[c](#tblfn3){ref-type="table-fn"}[@b0245])Cassiarin A0.023[a](#tblfn1){ref-type="table-fn"}, 0.005[b](#tblfn2){ref-type="table-fn"}\>100[c](#tblfn3){ref-type="table-fn"}, 35[e](#tblfn5){ref-type="table-fn"}[@b0245], [@b0240]Cassiarin B22.0[a](#tblfn1){ref-type="table-fn"}, 6.9[b](#tblfn2){ref-type="table-fn"}\>100[c](#tblfn3){ref-type="table-fn"}, \>100[e](#tblfn5){ref-type="table-fn"}[@b0245], [@b0240]Cassiarin C24.2[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}[@b0280])Cassiarin D3.6[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}[@b0280])Cassiarin E7.3[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}[@b0280])10,11-dihydroanhydrobarakol (DHB)2.3[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}[@b0280])Anhydrobarakol (ANH)4.7[a](#tblfn1){ref-type="table-fn"}, 7.8[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}Oshimi et al. (2009, [@b0280], [@b0285])5-acetonyl-7-hydroxy-2-methylchromone (AHMC)8.6[a](#tblfn1){ref-type="table-fn"}, 4.5[a](#tblfn1){ref-type="table-fn"}\>100[d](#tblfn4){ref-type="table-fn"}Oshimi et al. (2009, [@b0280], [@b0285])Chrobisiamone A2.6[a](#tblfn1){ref-type="table-fn"}--[@b0285])Cassiarin F3.3[b](#tblfn2){ref-type="table-fn"}\>50[d](#tblfn4){ref-type="table-fn"}[@b0100])[^2][^3][^4][^5][^6]Table 2The selected proteins with their PDB codes, resolution (Res.), co-crystallise ligand and self-docking RMSD values are provided in this table.ProteinPDBRes. (Å)Co-crystallized ligandMin. RMSD values1.Dihydroorotate dehydrogenase4CQ81.985-(4-Cyano-2-methyl-1*H*-benzimidazol-1-yl)-*N*-cyclopropylthiophene-2-carboxamide0.4062.Triosephosphate Isomerase1O5X1.10*Na*[f](#tblfn11){ref-type="table-fn"}3.PfA-M13T8V1.80*N*-\[(2-{2-\[(*N*-{(2*S*,3*R*)-3-amino-4-\[4-(benzyloxy)-phenyl\]-2-hydroxybutanoyl}-L-alanyl)amino\]ethoxy}ethoxy)acetyl\]-4-benzoyl-L-phenylalanyl-*N*~6~-hex-5-ynoyllysinamide1.3544ZW31.80*Tert*-Butyl \[(1*S*)-1-(4-bromophenyl)-2-(hydroxyamino)-2-oxoethyl\]-carbamate1.0804X2U1.50Tosedostat0.5114K5L1.91Phosphonic Arginine1.1604R5X1.853-amino-*N*-{(1*R*)-2-(hydroxyamino)-2-oxo-1-\[4-(1H-pyrazol-1-yl)-phenyl\]-ethyl}-benzamide1.4923EBH1.652-(3-Amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid0.8504.PfA-M174ZY22.10*N*-\[(1*R*)-2-(hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluorobiphenyl-4-yl)-ethyl\]-2,2-dimethylpropanamide1.0014X2T2.73Tosedostat0.7013KR42.002-(3-Amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid0.3964R762.503-Amino-*N*-{(1*R*)-2-(hydroxyamino)-2-oxo-1-\[4-(1*H*-pyrazol-1-yl)-phenyl\]-ethyl}-benzamide0.6125CBM2.30(2*S*)-2-{\[(*R*)-\[(*R*)-amino(phenyl)-methyl\]-(hydroxy)phosphoryl\]-methyl}-4-methylpentanoic acid0.8074K3N2.00{(*R*)-amino\[4-(1*H*-pyrazol-1-yl)-phenyl\]-methyl}-phosphonic acid1.2083T8W2.00*N*-((2*R*,3*S*,6*S*,18*S*,21*S*)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)-hex-5-ynamide1.4093Q431.8N-\[(2S,3R)-3-amino-2-hydroxy-4-(4-methoxyphenyl)-butanoyl\]-L-leucine0.8155.GMP synthetase3UOW2.72Xanthosine-5′-monophosphate0.7046.Enoyl-ACP Reductase3LT0[b](#tblfn7){ref-type="table-fn"}1.964-(2,4-dichlorophenoxy)-3-hydroxybenzaldehyde0.5601ZXB2.683-Chloro-4-(4-chloro-2-hydroxyphenoxy)-*N*-methylbenzamide0.7881V352.50Nicotinamide adenine dinucleotide (NADH)0.8184IGE[b](#tblfn7){ref-type="table-fn"}2.157-(4-Chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one0.5512NQ82.50Isoniazid-Nicotinamide adenine dinucleotide (INH-NAD)0.9141NHW2.352-(2,4-Dichloro-phenylamino)-phenol0.9072FOI2.504-(2,4-Dichlorophenoxy)-2′-methylbiphenyl-3-ol1.0207.Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase3AZB2.605-chloro-8-\[(3-chlorobenzyl)-oxy\]-quinoline0.6118.Prolyl-tRNA synthetase4OLF2.90Halofuginone1.2704WI11.651-(4-fluorophenyl)-3-\[4-(4-fluorophenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl\]-urea0.5019.PfHAD14ZEV1.80Mannose-6-Phosphate0.32310.Spermidine synthetase4BP31.75Decarboxylated *S*-adenosyl-methionine0.9013RIE1.905′-deoxy-5′-methylthioadenosine0.8182I7C1.71*S*-adenosyl-1,8-diamino-3-thiooctane0.4502HTE2.005′-deoxy-5′-methylthioadenosine0.51211.CDPK44QOX2.753-(3-bromobenzyl)-1-*tert*-butyl-1H-pyrazolo-\[3,4-*d*\]pyrimidin-4-amine0.71712.CDPK24MVF2.00Staurosporine0.82513.HSP903PEH2.752-amino-4-{2,4-dichloro-5-\[2-(diethylamino)-ethoxy\]-phenyl}-*N*-ethylthieno\[2,3-*d*\]-pyrimidine-6-carboxamide0.3093PEJ2.81Macbecin0.5323K602.30Adenosine diphosphate (ADP)0.5993IED2.01Adenylyl-Imidodiphosphate (AMPPN)1.40214.Fructose-1,6-bisphosphate aldolase4TR92.11*N*′-\[(*E*)-(2,4-dichlorophenyl)-methylidene\]-3,4-dihydroxybenzohydrazide0.37315.Ferredoxin-NADP+ reductase2OK82.40Nicotinamide adenine dinucleotide phosphate (NADP)1.0072OK72.70Adenosine-2′-5′-Diphosphate (2'-ADP)0.64116.Dihydrofolate reductase-thymidylate synthase (PfDHFR-TS)1J3I2.33WR992100.5133UM82.6Cycloguanil0.9983QGT2.3Pyrimethamine1.6043DGA2.7*N*-\[2-chloro-5-(trifluoromethyl)-phenyl\]imidodicarbonimidic diamide1.2004DPD2.5Dihydrofolic acid0.88817.D-aminoacyl-tRNA deacylase (DTD)4NBI1.863′-deoxy-3′-(D-tyrosylamino)-adenosine0.7113LMV2.834-(2-Hydroxyethyl)-1-piperazine ethanesulfonic acid1.3023KO32.09Adenosine triphosphate (ATP)1.0093KO52.8ADP0.97718.FK5064QT31.40Rapamycin0.2214J4N2.75N-(2-ethylphenyl)-2-(3H-imidazo\[4,5-b\]pyridin-2-ylsulfanyl)acetamide0.7082VN12.358-Deethyl-8-\[but-3-enyl\]-ascomycin0.89019.Lactate dehydrogenase1T241.704-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid0.9011XIV1.702-({4-Chloro-2-\[hydroxy(methoxy)methyl\]cyclohexyl}amino)ethane-1,1,2-triol0.9901CET2.05Chloroquinein^€^1.3131LDG1.74NADH1.6074B7U1.88Bicine0.78020.PfPK51V0O1.90Indirubin-*5*-sulphonate0.44921.Plasmepsin II1LF21.803-amino-*N*-{4-\[2-(2,6-dimethyl-phenoxy)-acetylamino\]-3-hydroxy-1-isobutyl-5-phenyl-pentyl}-benzamide0.7604CKU1.855-\[1,1-bis(oxidanylidene)-1,2-thiazinan-2-yl\]-N3-\[(2S,3R)-4-\[2-(3-methoxyphenyl)propan-2-ylamino\]-3-oxidanyl-1-phenyl-butan-2-yl\]-*N*~1~,*N*~1~-dipropyl-benzene-1,3-dicarboxamide0.8312BJU1.56*N*-(*R*-carboxy-ethyl)-*α*-(*S*)-(2-phenylethyl)0.4512IGX1.705-Pentyl-*N*-{\[4′-(piperidin-1-yl-carbonyl)biphenyl-4-yl\]methyl}-*N*-\[1-(pyridin-2-ylmethyl)piperidin-4-Yl\]pyridine-2-carboxamide1.22222.Plasmepsin I3QS13.10KNI-10,0060.61923.Plasmepsin IV1LS52.80Pepstatin A0.87024.Phosphoglycerate Kinase1LTK3.00AMP0.39125.Glutathione reductase1ONF2.60Flavin Adenine Dinucleotide (FAD)0.90426.Thymidylate Kinase2YOG1.501-\[4-Chloranyl-3-(trifluoromethyl)-phenyl\]-3-\[\[(2*R*,3*S*)-5-\[5-methyl-2,4-*bis*-(oxidanylidene)pyrimidin-1-yl\]-3-oxidanyl-oxolan-2-yl\]methyl\]thiourea0.602WWF1.89ADP0.83227.Ubiquitin Carboxyl-Terminal Hydrolase 3 (Uchl3)2WDT2.30*Na*[f](#tblfn11){ref-type="table-fn"}28.Purine Nucleoside Phosphorylase2BSX2.00Inosine0.4561Q1G2.023,4-Dihydroxy-2-\[(methylsulfanyl)methyl\]-5-(4-oxo-4,5-dihydro-3H-pyrrolo \[3, 2-*d*\]pyrimidin-7-yl)pyrrolidinium0.70229.Histo-Aspartic Protease (Hap)3QVI2.50KNI-10,3950.31530.Purine Phosphoribosyltransferase1CJB2.00(1*S*)-1(9-deazahypoxanthin-9-yl)1,4-dideoxy-1,4-imino-D-ribitol-5-phosphate0.6113OZG1.99\[(3*S*)-4-Hydroxy-3-{\[(4-oxo-4,5-dihydro-3H-pyrrolo\[3,2-d\]pyrimidin-7-yl)methyl\]amino}butyl\]phosphonic acid0.94231.Peptide Deformylase1RL42.182-{*N*′-\[2-(5-amino-1-phenylcarbamoyl-pentylcarbamoyl)-hexyl\]-hydrazinomethyl}1.4-hexanoic acid-(5-amino-1-phenylcarbamoyl-pentyl)-amide0.66432.Cyclophilin1QNG2.10Cyclosporin A0.78233.Glutathione-S-Transferase4ZXG1.70Ligandin0.56034.Glyceraldehyde-3-Phosphate Dehydrogenase1YWG2.60Nicotinamide Adenine Dinucleotide (NAD)1.10435.Ribose 5-phosphate isomerase2F8M2.09*Na*[f](#tblfn11){ref-type="table-fn"}36.MTIP4R1E1.985-{\[(2-aminoethyl)-sulfanyl\]methyl}furan-2-carbaldehyde0.30937.Guanylate Kinase1Z6G2.184-(2-Hydroxyethyl)-1-piperazine ethanesulfonic acid0.65538.ARO (armadillo repeats only protein)5EWP1.80*Na*[f](#tblfn11){ref-type="table-fn"}39.cGMP-dependent protein kinase4OFG2.0Cyclic Guanosine Monophosphate (cGMP)0.83140.Apical membrane antigen 14Z0E1.9*Na*[f](#tblfn11){ref-type="table-fn"}4R191.8*Na*[f](#tblfn11){ref-type="table-fn"}41DXR5JAZ1.4\[(2*R*)-2-{2-\[hydroxy(methyl)amino\]-2-oxoethyl}-5-(naphthalen-1-yl)pentyl\]phosphonic acid0.5614Y671.6\[(2*R*)-2-{2-\[hydroxy(methyl)amino\]-2-oxoethyl}lo-5-phenylpentyl\]phosphonic acid0.4104KP72.0\[(*S*)-({2-\[hydroxy(methyl)amino\]-2-oxoethyl}sulfanyl)(phenyl)methyl\]phosphonic acid0.7013WQR1.97\[(1*S*)-4-\[hydroxy(methyl)amino\]-1-(4-methoxyphenyl)-4-oxobutyl\]phosphonic acid0.8094GAE2.30\[(1*S*)-3-\[acetyl(hydroxy)amino\]-1-(pyridin-4-yl)propyl\]phosphonic acid[e](#tblfn10){ref-type="table-fn"}0.677\[(1*R*)-3-\[acetyl(hydroxy)amino\]-1-(pyridin-4-yl)propyl\]phosphonic acid[e](#tblfn10){ref-type="table-fn"}0.7193AU91.903-\[formyl(hydroxy)amino\]propylphosphonic acid0.88442.kelch protein4YY81.81*Na*[f](#tblfn11){ref-type="table-fn"}43.Pf414YS42.45*Na*[f](#tblfn11){ref-type="table-fn"}44.Pf122YMO1.90*Na*[f](#tblfn11){ref-type="table-fn"}45.PfGrx14MZB1.043-\[*N*-morpholino\]-propane sulfonic acid0.69846.Tryptophanyl-tRNA synthetase4JFA2.60Tryptophan1.0194J752.40Tryptophanyl-5′-AMP0.71947.Tyrosyl-*t*RNA Synthetase3VGJ2.21Tyrosyl-AMP1.10248.Phosphoethanolamine Methyltransferase4FGZ1.99Amodiaquine0.3593UJB1.52*S*-adenosyl-L-homocysteine0.90249.MIF2WKF2.05*Na*[f](#tblfn11){ref-type="table-fn"}50.Peroxiredoxin4D731.80*Na*[f](#tblfn11){ref-type="table-fn"}51.Glycerol-3-Phosphate Dehydrogenase1YJ82.85*Na*[f](#tblfn11){ref-type="table-fn"}52.6-Pyruvoyl Tetrahydropterin Synthase (PTPS)1Y132.20Biopterin0.77253.Phosphoglycerate Mutase3EOZ2.40*Na*[f](#tblfn11){ref-type="table-fn"}54.Diadenosine Triphosphate Hydrolase5CS21.65Cyclomarin A0.49055.Aspartate Transcarbamoylase5ILQ2.50*Na*[f](#tblfn11){ref-type="table-fn"}56.Plasmodium Falciparum Rab61D5C2.30Guanosine Diphosphate (GDP)0.70557.Acyl-COA Binding Protein1HBK2.00Coenzyme A0.66758.Pfg271N812.10*Na*[f](#tblfn11){ref-type="table-fn"}59.Fab Complex Whith Plasmodium Falciparum Msp1-191OB12.90*Na*[f](#tblfn11){ref-type="table-fn"}60.Adenylosuccinate synthetase1P9B2.006-Phosphoryl-Inosine Monophosphate0.44361.Nucleoside diphosphate kinase B1XIQ3.05*Na*[f](#tblfn11){ref-type="table-fn"}62.D-Ribulose 5-Phosphate 3-Epimerase1TQX2.00*Na*[f](#tblfn11){ref-type="table-fn"}63.GTPase Rab61D5C2.30GDP0.54864.GTPase Rab113BFK1.80GDP1.00165.Rab5 protein3CLV1.89GDP0.67066.RabGDI3P1W1.85*Na*[f](#tblfn11){ref-type="table-fn"}67.Orotidine 5′-Monophosphate Decarboxylase3VI22.104-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid0.4872Q8Z1.86-Amino-UMP0.8613S9Y1.76-amino-5-fluorouridine 5′-(dihydrogen phosphate)0.9142ZA12.65Orotidine 5′-monophosphate0.50368.Oxoacyl-Acp Reductase2C071.50*Na*[f](#tblfn11){ref-type="table-fn"}69.ClpP protease catalytic domain from Plasmodium falciparum2F6I2.45*Na*[f](#tblfn11){ref-type="table-fn"}70.Glutamate Dehydrogenase2BMA2.70*Na*[f](#tblfn11){ref-type="table-fn"}71glutamate dehydrogenase 23R3J3.10*Na*[f](#tblfn11){ref-type="table-fn"}72.PHIST4JLE2.35*Na*[f](#tblfn11){ref-type="table-fn"}73.PF3D7_0823300 (GCN5)[a](#tblfn6){ref-type="table-fn"}*^,^*[c](#tblfn8){ref-type="table-fn"}4QNS1.50*Na*[f](#tblfn11){ref-type="table-fn"}Histone acetyltransferase GCN55TPX2.10(1S, 2S)-*N*~1~, *N*~1~-dimethyl-*N*~2~-(3-methyl-\[1,2,4\]triazolo\[3,4-*a*\]phthalazin-6-yl)-1-phenylpropane-1,2-diamine0.79974.PFA0510w (Bromodomain protein)[a](#tblfn6){ref-type="table-fn"}4PY62.50*Na*[f](#tblfn11){ref-type="table-fn"}75.PF3D7_14756004NXJ2.18*Na*[f](#tblfn11){ref-type="table-fn"}76.PF10_03283FKM2.50*Na*[f](#tblfn11){ref-type="table-fn"}77.Ubiquitin conjugating enzyme UBC94M1N1.50*Na*[f](#tblfn11){ref-type="table-fn"}78.Ubiquitin conjugating enzyme E22H2Y2.80*Na*[f](#tblfn11){ref-type="table-fn"}79.Ubiquitin carrier protein2R0J1.85*Na*[f](#tblfn11){ref-type="table-fn"}80.Ubiquitin conjugating enzyme e2[a](#tblfn6){ref-type="table-fn"}2Q0V2.40*Na*[f](#tblfn11){ref-type="table-fn"}81.PF10_0330 (Ubiquitin-conjugating enzyme)[a](#tblfn6){ref-type="table-fn"}2ONU2.38*Na*[f](#tblfn11){ref-type="table-fn"}82.Falcilysin (protein)3S5M1.55*Na*[f](#tblfn11){ref-type="table-fn"}83.Calcium-dependent protein kinase 33 K211.15*Na*[f](#tblfn11){ref-type="table-fn"}84.Calcium-dependent protein kinase[a](#tblfn6){ref-type="table-fn"}3MSE2.10*Na*[f](#tblfn11){ref-type="table-fn"}85.Pyruvate kinase3KHD2.70*Na*[f](#tblfn11){ref-type="table-fn"}86.Calcium-dependent protein kinase 23PM82.00*Na*[f](#tblfn11){ref-type="table-fn"}87.ADP-Ribosylation Factor 13LRP2.50GDP0.75888.Aspartate Aminotransferase3K7Y2.80Pyridoxal phosphate (PLP)1.00989.PFC0360w protein (HSP90 Activator protein)3NI82.50*Na*[f](#tblfn11){ref-type="table-fn"}90.MAP-2 kinase3NIE2.30Phosphoaminophosphonic acid-adenylate ester0.41791.Serine/threonine kinase-13LLT2.50Phosphoaminophosphonic acid-adenylate ester0.85792.Ornithine delta-aminotransferase3LG02.30*Na*[f](#tblfn11){ref-type="table-fn"}93.Aha-13N721.77*Na*[f](#tblfn11){ref-type="table-fn"}94.Arginase3MMR2.142(*S*)-amino-6-boronohexanoic acid0.6373SL11.906-(dihydroxyboranyl)-2-methyl-L-norleucine1.37795.Malarial Clpb2 Atpase/Hsp101 Protein4IRF1.65*Na*[f](#tblfn11){ref-type="table-fn"}96.ClpB protein (Green fluorescent protein)[a](#tblfn6){ref-type="table-fn"}4XBI1.80*Na*[f](#tblfn11){ref-type="table-fn"}97.Maltose-binding periplasmic protein4O2X2.70*Na*[f](#tblfn11){ref-type="table-fn"}98.Aquaglyceroporin3C022.05*β*-Octylglucoside1.11099.Profilin2JKG1.89*Na*[f](#tblfn11){ref-type="table-fn"}100.Microtubule-associated protein 1 light chain 34EOY2.22*Na*[f](#tblfn11){ref-type="table-fn"}101.Thrombospondin related anonymous protein4F1J1.73*Na*[f](#tblfn11){ref-type="table-fn"}102.Apicoplast TIC22[a](#tblfn6){ref-type="table-fn"}4E6Z2.15*Na*[f](#tblfn11){ref-type="table-fn"}103.Diphenyl Nucleoside3T641.652′, 5′-Dideoxy-5′-\[(diphenylmethyl)amino\]-uridine0.5982Y8C2.105′-Tritylated Deoxyuridine Analogue0.617104.Erythrocyte Binding Antigen Region II Region 1754K2U2.25*Na*[f](#tblfn11){ref-type="table-fn"}1ZRO2.25*α*-2,3-sialyllactose0.8961VYQ2.402,3-deoxy-3-fluoro-5-*O*-trityluridine1.006105.Erythrocyte Membrane Protein 13CPZ2.80*Na*[f](#tblfn11){ref-type="table-fn"}106.Erythrocyte Binding Antigen 1404JNO3.00*O-*sialic acid1.017107.Dbl6 Epsilon Domain (VAR2CSA)2Y8D1.84*Na*[f](#tblfn11){ref-type="table-fn"}2XU02.06*Na*[f](#tblfn11){ref-type="table-fn"}108.MSPDBL23VUU2.09*Na*[f](#tblfn11){ref-type="table-fn"}109.Erythrocyte Membrane Protein-1 (PfEMP1) variant 2 of strain MC3C642.40*Na*[f](#tblfn11){ref-type="table-fn"}110.2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF)4C811.56Cytidine-5′-diphosphate1.308111.Thioredoxin reductase4J562.37FAD1.100112.Thioredoxin-24O322.20*Na*[f](#tblfn11){ref-type="table-fn"}113.Thioredoxin Peroxidase 22C0D1.78*Na*[f](#tblfn11){ref-type="table-fn"}114.Peroxiredoxin1XIY1.80*Na*[f](#tblfn11){ref-type="table-fn"}115.Thioredoxin like protein[a](#tblfn6){ref-type="table-fn"}3CXG2.00*Na*[f](#tblfn11){ref-type="table-fn"}116.Thioredoxin like protein[a](#tblfn6){ref-type="table-fn"}1SYR2.95*Na*[f](#tblfn11){ref-type="table-fn"}117.Peptidase[a](#tblfn6){ref-type="table-fn"}5JR62.30*Na*[f](#tblfn11){ref-type="table-fn"}118ATP-dependent Clp protease4GM22.80*Na*[f](#tblfn11){ref-type="table-fn"}119GAP503TGH1.70*Na*[f](#tblfn11){ref-type="table-fn"}120.Tumor protein (TCTP)3P3K2.55*Na*[f](#tblfn11){ref-type="table-fn"}121.ARF GTPase activating protein3SUB2.40*Na*[f](#tblfn11){ref-type="table-fn"}122.Sir2A3U312.20NAD0.709123.Ser/Thr protein kinase2PMO2.90Hymenialdisine0.993124.Adenylate Kinase3TLX2.75ADP0.9891CJB2.00(1*S*)-1(9-Deazahypoxanthin-9yl)1,4-dideoxy-1,4-imino-d-ribitol-5-phosphate0.6402VFA2.80Guanosine Monophosphate (GMP)1.082125.Apicomplexan AP2 protein3IGM2.40*Na*[f](#tblfn11){ref-type="table-fn"}126.Nucleosome assembly protein 1[a](#tblfn6){ref-type="table-fn"}3FS32.30*Na*[f](#tblfn11){ref-type="table-fn"}127.Nucleosome assembly protein3KYP2.80*Na*[f](#tblfn11){ref-type="table-fn"}128.Falcipain (*Isoform-2*)3BPF2.90*N*-\[*N*-\[1-Hydroxycarboxyethyl-carbonyl\]leucylamino-butyl\]-guanidine0.613(*Isoform-3*)[d](#tblfn9){ref-type="table-fn"}3BWK2.43*N*-2-(Morpholin-4-ylcarbonyl)-*N*-\[(3*S*)-1-phenyl-5-(phenylsulfonyl)pentan-3-yl\]-L-leucinamide0.706129.Glycerol Kinase2W412.41ADP0.83130.Malaria Sporozoite Protein Uis3[a](#tblfn6){ref-type="table-fn"}2VWA2.50Phosphatidylethanolamine1.502131.EBA-175 region VI2RJI1.80*Na*[f](#tblfn11){ref-type="table-fn"}132.Pyrroline carboxylate reductase2RCY2.30NADP0.906133.Phosphatidylethanolamine-Binding Protein2R771.60*Na*[f](#tblfn11){ref-type="table-fn"}134.Internal Kinesin1RY61.60*Na*[f](#tblfn11){ref-type="table-fn"}135.Dynein Light Chain 11YO31.65*Na*[f](#tblfn11){ref-type="table-fn"}136.Malarial Hypothetical protein1ZSO2.17*Na*[f](#tblfn11){ref-type="table-fn"}137.Adenosyl-homocysteinase1V8B2.40NAD1.205138.Fe-Superoxide Dismutase2GOJ2.00*Na*[f](#tblfn11){ref-type="table-fn"}139.Ribosomal RNA Methyltransferase[a](#tblfn6){ref-type="table-fn"}2PLW1.70*S*-Adenosyl-L-homocysteine (SAM)0.666140.Protein-L-isoaspartate *O*-methyltransferase *β*-aspartate methyltransferase2PBF2.00SAM0.480141.Dimethyladenosine transferase[a](#tblfn6){ref-type="table-fn"}2H1R1.89*Na*[f](#tblfn11){ref-type="table-fn"}142.Plasmodial PLP Synthase2ABW1.62Tetraethylene glycol0.922143.Actin Depolymerizing Factor3Q2B1.60D(-)-tartaric acid0.801144.Glucose-6-phosphate isomerase3PR32.45Fructose-6-phosphate0.442145.Methionine aminopeptidase3S6B1.95*Na*[f](#tblfn11){ref-type="table-fn"}146.Nucleolar GTP-binding protein 1[a](#tblfn6){ref-type="table-fn"}2QU82.01GDP0.575147.Orotate Phosphoribosyl transferase4FYM2.60*Na*[f](#tblfn11){ref-type="table-fn"}[^7][^8][^9][^10][^11][^12]Table 3Energy profile of stereoisomers of Cassiarins isoforms.R-Cassiarins C*S-Cassiarins* CR-Cassiarins DS-Cassiarins DR-Cassiarins ES-Cassiarins E*R-DHBS-DHB*Cassiarins FStretch (E*~Str~*)0.81040.84292.90642.99171.99582.07690.94610.94612.4203Bend (E*~B~*)2.73843.02069.15699.35546.06656.26312.86782.86787.9539Stretch-Bend (E*~Str-B~*)0.08030.10620.30360.32190.17870.1957−0.0318−0.0318−0.0135Torsion (E*~tor~*)−8.4023−7.9008−12.7333−12.5845−17.7278−17.5754−4.5516−4.55160.0139Non-1,4 VDW (E*~nVDW~*)−3.9005−3.9103−5.2953−5.4962−8.6554−8.8469−3.4075−3.4075−12.05441,4 VDW (E*~VDW~*)15.975415.813230.338930.476132.873433.010916.745116.745128.1042Dipole/Dipole (E*~d-d~*)0.21670.2191−1.3802−1.2855−0.3444−0.3346−0.1735−0.1735−0.4288Total Energy (E = kcal/mol)7.51838.190723.297023.778814.386814.789612.394612.394625.9957[^13]

The energy minimisation step revealed the most stable conformation among the isomers of individual Cassiarins, see in [Table 3](#t0015){ref-type="table"}. In general, we found that *R*-stereoisomers have more energy minimised structures than their *S*-isoforms and DHB stereoisomers appeared to be unaffected with the *C*~2~-stereochemistry. The large structure containing isoforms show more energy penalties than their smaller isoforms, as follow: F \> D \> E \> DHB \> C, which seems reasonably obvious, as these have more steric hindrance in their structures. Also, we found certain isoforms consist similar structural connectivity but shows significant differences in their energy levels (*C vs* DHB; E *vs* D), indicating that the subtle alteration, like replacing of nitrogen as from *N*~1-~isoquinoline by oxygen, diminishes the aromatic character, which increases the cyclic ring constrain.

Based on the binding energies, resulted from three different docking placement methodologies, we considered and compare top 25 most energy minimised Cassiarin-protein complexes and selected only those ones which were present in the result of all three docking methods ([Table 4](#t0020){ref-type="table"} in [Supplementary information](#s0140){ref-type="sec"}). Based on these observations, we found 16 targets as for individual Cassiarin stereoisomer, listed in [Table 4](#t0020){ref-type="table"}. While [Table 5](#t0025){ref-type="table"}, summarises the basic structural features of these targets. The binding mode of Cassiarins with these protein targets has been discussed descriptively in the later sections of this article.Table 4The most common PDBs as targets were identified for Cassiarins isoforms/isomers.R-Cassiarins C*S-*Cassiarins CR-Cassiarins DS-Cassiarins DR-Cassiarins ES-Cassiarins E*R*-DHB*S*-DHBCassiarins F4J754J752W415EWP3UOW3LG03VGJ1P9B4j753VGJ3VGJ3PR32W413FS34Y673FS34Y673MMR3MMR3VUU4Y672W411P9B3MMR4Y674YY84YY84J754J752C073S6B4Y673LT03PR3Table 5Summary of individual protein target.PDBProtein/TargetCo-crystallise ligandStructural features and functions4J75Tryptophanyl-tRNA synthetaseTrptophanyl-Adenosine monophosphate (WAMP)•Utilises tryptophan as substrate•Contain 632 amino acids•Has KMSKS conserved loop and AIDQ motif in its active binding site3VGJTyrosyl-tRNA synthetaseTyrosyl-Adenosine monophosphate (YAMP)•Utilises tyrosine as substrate•Catalytic domain contains 18-260 amino acid residues•Has KMSKS conserved loop and AIDQ motif in its binding site4Y671-Deoxy-*D*-Xylose-5-phosphate reductoisomeraseFosmidomycin•Homodimer in its active form•Each monomer is made up of two large domains•One large domain for NADPH•Other one for catalysis•FOSMIDOMYCIN inhibitors are most studied class2W41Glycerol kinaseAdenine Diphosphate•Utilises glycerol as substrate•Participate in rate-limiting step in glycerol utilisation•Has 501 amino acid residues•Contains two domains separated by a deep cleft•Domain I (regions 1--262 and 436--471)•Domain II (regions 263--435 and 472--501)•Domain 1 is for glycerol binding; Domain II is for ADP binding.•Its kinase domain shows typical *H*-bond acceptor--donor triad interactions3MMR*Plasmodium falciparum Arginase*2-(*S*)-amino-6-boronohexanoic acid•Utilises binuclear manganese•Forms tetrahedral geometry with both the manganese atoms.•Close to human arginase I (28%) and II (27%)3FS3*Nucleosome Assembly Proteinn. a*•347amino acid long-dimer•Has two domains, domain I (mainly contain, dimerization helix-2, region started from 37 to 87)•Domain II, containing multiple *α*-helices and a subdomain containing four antiparallel *β*-strands (residues 128--185)1P9B*Adenylosuccinate synthetase*GDP and IMP•Consists of 19 strands (*β*~1~--*β*~19~), 12 *α*-helices and seven 3~10~ helices•It has nine parallel *β*-strands, with a tenth antiparallel strand (*β*~19~) form a central sheet.•Has 4 subdomains•Subdomains III (residues 278--302) majorly constitute ligand binding pocket•It has 2 binding sites: orthosteric (IMP binding site) and allosteric (GTP binding site).3PR3*Glucose-6-Phosphate Isomerase*Fructose-6-phosphate•Orthosteric site contains key amino acids, Glu380, Lys540, Thr233, Lsy232, Thr236, Ser231 and Gly158•Like, human glucose-6-phosphate isomerase (*Hs*G6PI), it also has two globular domains (as large and small domains) and an "arm-like" *C*-terminal tail4YY8*Kelch Motif Associated Protein of Plasmodium Falciparum*Mono-alkylated *p-*substituted sulphonamides•Made up of 28 *β-*strands where *β*~4~ to *β*~28~ involved in the formation of its 6 kelch motifs•Every motif contains 4 *β*-strands in common,•6 kelch motifs together built a propeller architecture3LG0*Ornithine δ-aminotransferase of Plasmodium falciparum (PfOAT)n. a*•Enzymatically active as a homodimer•High percentage of conserved residues in the active cavity, which is proximal to the interface between two subunits•Each subunit contains a pyridoxal-phosphate (PLP) binding domain and a substrate binding domain•PLP binding loop domain (region started from 287 to 293) and strictly conserved in all species3LT0*Enoyl Acyl Carrier Protein Reductase*Triclosan and NADPH•With its most studied class of inhibitor (triclosan derivatives), it shows formation of typically ternary complex of *Pf*ENR-NAD^+^-triclosan•Ring A of Triclosan binds to hydrophobic pocket and has *π*-stacking interaction distance with nicotinamide ring of the cofactor NAD^+^2C07*Oxoacyl Acyl-Carrier-Protein Reductase*Triclosan and NADPH•Most studies limited to triclosan and its derivatives.•Our comparative structural studies with *E.* coli found 4 key mutations: Ser99 (Gly41 in *E. coli*), Ser94 (Ala36 in *E. coli*), Arg95 (Thr37 in *E. coli*) and Ser198 (Gly137 in *E. coli*).5EWP*Armadillo Repeats Only Protein of Plasmodium Falciparumn. a*•252 amino acid residues long dimer•Contains 15 *α*-helixes, form a characteristic alpha solenoid structure•Each Armadillo repeat is composed of a pair of alpha helices that form a hairpin structure3S6B*Methionine Aminopeptidase 1bn. a*•Comparative studies with human homologous protein: Thr156 and Ser268 mutated in place of Pro192 and Cys301 (in human),3UOW*Guanosine monophosphate synthetase*Xanthose Monophosphate (XMP)•It is dimeric in nature.•Each monomer is composed of two catalytic domains, an *N*-terminal independent GATase (1--236) and a *C*-terminal ATPPase domain (237--555)•Its dimer form is highly required for its activity as the interface has 108*C*-terminal residues of the ATPPase domain.•In this interface, two *cis*-prolines (Pro548--Pro549) allow a tetrahedral configuration of Asp543, Thr551, Glu553 and Arg5393VUUMerozoite surface proteins have erythrocyte-binding Duffy Binding Like Domains (*MSPDBL2)n. a*•Assist parasite for its initial binding to the surface receptors on the host red blood cell.•Consist of a boomerang shaped *α*-helical core formed from three subdomains•Subdomain 1 (region 161--225) only contains a 5-residue long *α*-helix (helix 1) provide a junction for subdomains 2 and 3[^14]

3.2. Tryptophanyl-tRNA synthetase {#s0045}
---------------------------------

The cytosolic tryptophanyl-tRNA synthetase of *Plasmodium falciparum* (*Pf*-cTrpRNA, PDB: 4J75, *Res.*2.4 Å, ([@b0200])) belongs to aminoacyl tRNA synthetase (aaRSs) class, which charges amino acids to their cognate tRNAs during protein synthesis and requires a large conformational change during their functioning. Previous studies on bacterial and human *t*RNA synthetase revealed key structural features: (a) In bacteria, these have open, ligand-free state (F-state) where either Trptophan (Trp) or ATP can bind; (b) Simultaneous binding of Trp and ATP in the pre-transition state requires a conserved loop, KMSKS (^492^K^493^M^494^S^495^S^496^T in *P. falciparum* and ^349^K^350^M^351^S^352^A^353^S in humans) ([@b0085]) to close onto the active site and *C*-terminal domain moves toward the active site, containing Rossmann-fold domain; (c) After the intermediate tryptophanyl-adenylate (WAMP) formation, both the KMSKS loop and *C*-terminal domain move slightly away from the catalytic core to allow to release of the product (called, as P-state) ([@b0085]) (d) While in human cytoplasmic TrpRS (*Hs-c*TrpRS), the binding of Trp is mainly accompanied by the *N*-terminus and a conserved AIDQ motif. Phylogenetically, *Pf-c*TrpRS is more close to *Hs-c*TrpRS (∼44% identity) than the human mitochondrial TrpRS (∼16% identity) ([@b0200]).

According to literature ([@b0085]), the WAMP binds to the 28 key amino acid residues of *Pf-c*TrpRNA (highlighted as bold single letter amino acid code): (i) ^296^**YTGR**^300^**G** and ^317^**H**X**GH**X**I**^323^P in the tip of a loop between *β*~3~ and *α*5 (ii) ^341^**Q**X**S**XX**EK** (iii) ^415^**Y**XXX^419^**Q** (iv) ^450^**VPQG**X**D**^456^**Q**XXX^460^**F** (v) ^481^**VF**^483^**M** (vi) ^492^**K**^493^**M**, as shown in [Fig. 2](#f0010){ref-type="fig"}(A) and as follow: (a) The indole and adenine ring has *π*-*π* interactions with Tyr306, Phe482; (b) The free NH~2~ and *N*~1~-heteroatom of adenine ring has *H*-bond interaction with backbone of Met483; (c) The hydroxyl (*OH*) groups of ribose sugar shows *H*-bonding with *β*-COOH of Asp455 and backbone of Glu452; (d) The phosphate head lies within *H*-bond distance with side chain of Arg309 and backbone of Gly310; (e) The NH~2~ tethered functionality of tryptophan interacts with Gln429. Like adenine ring of WAMP, tetracyclic core of Cassiarin-F (Orange) faces vertically to the *β~7~*-strand region extended from ^481^Val to ^496^Thr and *α*~5~-helix from ^318^Leu to ^334^Phe and also, has T-shaped *π*-*π* interactions with Phe482 (3.89 Å) and His320 (3.23 Å) ([@b0335]), see in [Fig. 2](#f0010){ref-type="fig"}(B). The *N*~1~-isoquinoline of tetracyclic ring of Cassiarin-F faces towards a cavity consist *β~6~*-strand (region from ^448^Cys to ^453^Gly), ^453^GID^456^Q conserved motif, *α*~11~-helix (region from ^456^Q to ^470^M) and has *H*-bond acceptor interaction with N*H*~2~ terminus of the side chain of Gln456 (3.02 Å). The resorcinol phenolic-O*H* inclined towards the *β*~4~-strand (region from ^337^Pro to ^342^Leu), *α~6~*-helix (^343^Ser to ^350^Phe), showing *H*-bond donor interaction with *γ-COOH* acid side chain of Glu346 (2.43 Å). The extended propanone functionality aligned with *β*~3~-strand (^304^Tyr to ^309^Arg), has *H*-bond acceptor interaction with guanidine side chain of Arg309 (1.95 Å) and amide backbone of Gly310 (2.09 Å). While the tricyclic ring of *R*-Cassiarin-C shows reverse orientation: (a) phenolic ring fitted into a pocket surrounded by *α*~11~ (region from ^456^Q to ^470^M) and conserved motif GIDQ, showing *H*-bond donor interactions with alcoholic side chain of Thr307 (2.39 Å; *β*3 strand) and amide backbone of Pro451 (2.39 Å; *β*~6~: ^448^Cys to ^453^Gly), while its *N*~1~-isoquinoline ring projected outwards, as shown in [Fig. 2](#f0010){ref-type="fig"}(C). Although, the *S*-isomer of Cassiarin-C attained a reasonable conformational binding change, as phenolic O*H* projected towards the *α*~6~-helix and involved with *γ*-COOH group of Glu346 (2.32 Å), but its *N*~1~-isoquinoline ring has *H*-bond acceptor interaction with Thr307 (2.76 Å) of *β~3~*-strand and utilisation of conserved motif GIDQ, shows similar binding pocket like *R*-isomer-C, shown in [Fig. 2](#f0010){ref-type="fig"}(D). The heteroatom (*N*~1~) replacement with oxygen atom in Cassiarin-C, brings *R*-DHB, which restricted the phenolic ring, aromatic character due to formation of quinone ring and also affected its binding with *Pf-c*TrpRNA. However, its binding resembles to the 2-resorcinol propanone substructure of Cassiarin F binding, as the carbonyl (C*O*) of quinone utilises *ε*-N*H*~2~ of Lys347 (2.48 Å) of *β*~6~-strand and have proximity with the conserved motif GIDQ, *α*~11~, *α*~6~ and *β*~3~, as shown in [Fig. 2](#f0010){ref-type="fig"}(E). Although, as it is devoid of tetracyclic ring like in Cassiarin-F therefore the interactions with of *β*~7~ region and *α*~5~ got disappeared. The *S*-DHB has shown a close identity in its binding pattern like *R*-DHB, which would therefore similarly mimic interactions as like 2-resorcinol propanone of Cassiarin F, with slight variation in its binding conformation as resulted by the modification of *C*~2~-stereochemistry, see in [Fig. 2](#f0010){ref-type="fig"}(F). The close binding behaviour of both isomers of DBH with regards to the 2-resorcinol propanone of Cassiarin-F, offers a possible bioisostere substitution on tetracyclic core of Cassiarin-F in order, to improve structure based rational design against *Pf-c*TrpRNA protein in *P. falciparum*. Additionally, we observed that *S*-DHB binding within the *π*-stacking interaction to the Tyr425 residue, which is deleted in human aminoacyl tRNA synthetase proteins and can be utilised as a structural feature in optimisation of NCE.Fig. 2Illustrating the interaction of the various ligands with tRNA synthetase: (A) Binding of WAMP (B) Binding of Cassiarin F (Orange) (C) Binding of *R*-Cassiarin C (Blue), (D) Binding of *S-*Cassiarin C (Violet), (E) Binding of *R*-DHB (Cyan); (F) Binding of *S*-DHB (Brown).

3.3. Tyrosyl-tRNA synthetase {#s0050}
----------------------------

Tyrosyl-tRNA synthetase (PDB: 3VGJ, *Res*. 2.21 Å, ([@b0020]) belongs to the aminoacyl tRNA synthetase family proteins and therefore have similar function and catalytic motifs as seen in previous case of *Pf*-*c*TrpRNA, except its utilisation of tyrosine at the place of tryptophan, in the form of tyrosyl-AMP. It consists of a catalytic domain region started from residues 18--260, contains KMSKS and GIDQ conserved motifs. Also, as obvious, its nucleoside binding pocket interactions are similar like *Pf*-*c*TrpRNA ([Fig. 3](#f0015){ref-type="fig"}(A)), as (a) adenosine ring fits in the cavity constituted by Lys247, Leu238, Met 237, Gly236 and Met248 of complimentary K^247^M^248^SKS conserve domain ([Fig. 3](#f0015){ref-type="fig"}(B)); (b) The His70, Ala72 and Gln73 which lies at the tip of loop between *α*~1~-helix/*β*~3~-stand and Leu206, Asp209, Gln2010 of evolutionary conserved residues ^207^GI^209^D^2010^Q create its sugar binding pocket; (c) Asp61, Phe63, Glu64 encloses the sugar-phosphate junction and phosphate head; (d) The Gln192, Asp195 located on the top of ionised N*H*~2~ of tyrosine where the Trp94, Ala96, Ph99 composed hydrophobic pocket in order to accommodate aromatic phenol ring.Fig. 3(A) Superposition of active site domain of Tyrosyl-tRNA synthetase (secondary structure ribbon colour; grey colour code for co-crystallise ligand) and *Pf*-*c*TrpRNA (secondary structure in green colour; brown colour code for co-crystallise ligand); (B) interactive mode of co-crystallise ligand with Tyrosyl-tRNA synthetase.

The molecular docking of *R*-Cassiarin-C has shown *H*-bond donor interactions with Thr307 and Gln452 through its phenolic (O*H*) group, as shown in [Fig. 4](#f0020){ref-type="fig"}(A). As compared to *R*-isomer, *S-*Cassiarin-C shows more suitability for AMP binding pocket, as: (a) its phenolic (OH) orientated similarly like phosphate heads and has *H*-bond acceptor-donor interactions with side chain of Lys77 (2.72 Å) and free COOH terminus of Arg61 (2.67 Å), (b) The pyridine ring of its isoquinoline core binds like adenosine ring of AMP as it utilises His70 (T-shaped *π*-*π* interaction, 3.59 Å) and Lys247 (*H*-bond acceptor interaction, 2.67 Å) of KMSKS conserved motif, shown in [Fig. 4](#f0020){ref-type="fig"}(B) ([@b0335]). Similar to *S-*Cassiarin-C, the binding conformation of *R*-DHB also utilises AMP binding pocket, as: (a) quinone has *H*-bond acceptor interaction with Gly207 backbone (2.03 Å); (b) The 2-methyl-2*H*-pyran ring mimic the adenosine ring binding region through *H*-bond acceptor interaction with the side chain of Lys247(2.02 Å), see in [Fig. 4](#f0020){ref-type="fig"}(C).Fig. 4Molecular binding poses: (A) *R*-isomer of Cassiarins-C (blue) shows its utilises the GIDQ conserved domain (presence of Asp209, Gln210); (B) S-isomer (violet) of Cassiarins-C binds to adenosine monophosphate cavity; (C) *R*-DHB (cyan).

3.4. 1-Deoxy-D-xylose-5-phosphate reductoisomerase (DXR) {#s0055}
--------------------------------------------------------

DXR (PDB: 4Y67, *Res.* 1.6 Å, ([@b0060])) is a class B dehydrogenase enzyme, which exists as a homodimer in its active form (the active region started from Lys75 to Ser488) where each monomer is made up of two large domains separated by a cleft containing a deep pocket, a linker region, and a small *C*-terminal domain ([@b0060]). One of the large domain is responsible for NADPH binding (region started from 77 to 230), and the other domain is for catalysis (contains, metal and substrate binding, region started from 231 to 369). The catalytic domain is an *α*/*β*-type structure, consisting of five *α*-helices (*α*~7~--*α*~11~) and four *β*-strands (*β*~8~--*β*~11~) and have two different conformations, open and closed. The open conformation assist the substrate *D*-xylose-5-phosphate (DXP) to enter and binds to the active site ([@b0230]; [@b0345]). On the other hand, the NADPH binding site, contain conserved residues (Asp231, Glu233, Ser269, Ser270, Trp296, Met298, Ser306, Asn311, Lys312, and Glu315), which are also conserved in all human malaria parasites ([@b0400]; [@b0220]).

However, the most studied inhibitor class, fosmidomycin and its analogues bind in a typical fashion to DXR protein ([@b0060]), which can further categorised into three regions (a) phosphate head (PO~4~) binding region, which has tight *H*-bond interaction network with Ser270, Asn311, two water molecules, and His293; (b) hydrophobic carbon backbone binding region, which runs parallel to the indole ring of Trp296 and interacts with Met298; (c) hydroxamate binding pocket, which coordinated in *cis*-arrangement with metal ion (Mg^2+^ or Mn^2+^), negatively charged residues (Asp231, Glu233, and Glu315) and forms a typical distorted trigonal bipyramidal geometry for these class of compounds ([Fig. 5](#f0025){ref-type="fig"}(A)).Fig. 5Interactive binding mode: (A) Co-crystallise fosmidomycin derivative (gold); (B) Cassiarin F (Orange); (C) *R*-Cassiarin-C (Blue).

The molecular docking of Cassiarin-F shows its resorcinol phenolic functionality utilises majorly hydroxamate binding region, as characterised by its *H*-bond interaction with the backbone of Ser269 (3.18 Å), His341 (2.65 Å) and side chain (O*H*) of Ser232 (2.66 Å), as shown in [Fig. 5](#f0025){ref-type="fig"}(B). Also, its hydrophobic tetracyclic ring aligns parallel to the Trp296 and Met360, as same like the hydrophobic carbon backbone of the fosmidomycin analogues. Similarly, like Cassiarin-F, the *R*-Cassiarin-C phenol ring fits into the hydroxamate binding region as through the *H*-bond acceptor/donor interactions with free --N*H*~2~ side chain of Lys205 and --C*OO*H functionality of Asp231 respectively. While, the isoquinoline ring of *R*-Cassiarin-C participates in *π*-*π* interaction with Trp296 (3.86 Å & 4.45 Å), which shows its ring orientation different from the F-isoform, in [Fig. 5](#f0025){ref-type="fig"}(C). This indicates the pivotal role of additional aryl ring system (i.e. the extended propanone-resorcinol structure of Cassiarin-F), is a key difference for the such binding conformation of Cassiarin-F when compared to the binding conformation of *R*-Cassiarin-C.

Structurally, Cassiarin-C and Cassiarin-D are only different at *C*~2~-position substitution with 5-propenone-7-hydroxy-4*H*-chromen-4-one. The molecular docking of *S-*Cassiarin-D shows the 5-propenone functionality imitate like phosphate head and binds to Ser270 (side chain (1.61 Å) and backbone (1.92 Å)), backbone of Gly271 (2.54) and side chain (O*H*) of Ser269 (2.37) *via* H-bond acceptor interactions. While, the non-aromatic quinone interact with N*H*~2~-terminal of Glu233 (2.83 Å) through *H*-bond acceptor interaction. It appears that *C*~2~ extension from Cassiarin-C to Cassiarin-D pushed the tricyclic isoquinoline core more towards the NADPH binding pocket region (as provided with the presence of Ser88 and Ile89 from the of NADPH binding site) and, also aligned with the hydrophobic backbone patch (presence of Trp296 and Met360), shown in [Fig. 6](#f0030){ref-type="fig"}(A). However, *H*-bond acceptor interaction of *N*~1~-isoquinoline with N*H*-indole side chain of Trp296 (1.90 Å), shows the tricyclic ring tossed up from the cavity, which could be interesting to observe in case of co-binding of NADPH as its adenine ring would be close within 4.5 Å distance for *π*-*π* interaction with isoquinoline ring of *S*-Cassiarin-D. While in case of *R*-DHB, the quinone ring binds to phosphate head region *via H*-bond acceptor interaction with side chain of Ser270 (3.08 Å), backbone of Ser269 (2.03 Å) and N*H*~2~-terminus of side chain of Lys312 (2.34 Å), in [Fig. 6](#f0030){ref-type="fig"}(B). Additionally, the incorported *O*xygen atom of 2*H*-dihydropyran core of *R*-DHB shares a *H*-bond acceptor interactions with side chain of Ser232. Also, it has been found interesting that the interactive mode of *R*-DBH couldn't find characteristic hydrophobic backbone binding residues like Trp296 and Met360 within 4.5 Å. However, in case of molecular binding of *S*-DHB, quinone ring interacts (N*H*2 terminal of Lys 205 (2.63 Å) and Asn311 (2.89 Å)), *via H*-bond acceptor interactions, similarly like quinone ring of *R*-isomer, shown in [Fig. 6](#f0030){ref-type="fig"}(C) and [Fig. 6](#f0030){ref-type="fig"}(B), respectively, but its *C*~2~ associated pyran ring proximity to the Trp296 (hydrophobic interactions, 3.58 Å and 4.05 Å) and Met360, shows the critical role of *C*~2~ stereochemistry in their binding to the DXR protein, as it was not seen in *R*-isomer. We also found these Cassiarins binding lacks the utilisation of hydroxamate cavity of DXR protein and hence unable to coordinate with Mn^2+^ ions and to form typical trigonal bipyramidal geometry, as seen in fosmidomycin class inhibitors.Fig. 6Binding mode: (A) *S-*Cassiarin-D (green); (B) *R*-DHB (cyan); (C) S-DHB (brown).

3.5. Glycerol kinase (PfGK) {#s0060}
---------------------------

*Pf*GK (PDB: 2 W41, *Res*. 2.41 Å, ([@b0315])) phosphorylate the glycerol, which is a rate-limiting step in glycerol utilisation in parasite metabolism ([@b0315]; [@b0255]). Deletion of host gene shows no effect on gametocyte development, suggesting that these life cycle stages do not utilize host-derived glycerol as a carbon source ([@b0315]). The structural architecture of *Pf*GK contains 501 amino acid residues, arranged in two domains separated by a deep cleft. Each domain is constructed around a *α*/*β* core (characterise as *βββαβαβα*) that is characteristic of the sugar kinase/Hsp70/actin superfamily proteins ([@b0025]; [@b0155]). The Domain I (regions 1--262 and 436--471) comprises *β*~3~*β*~2~*β*~1~*α*~1~*β*~5~*α*~6~*β*~12~*α*~9~ and domain II (regions 263--435 and 472--501) consists of *β*~16~*β*~14~*β*~13~*α*~12~*β*~19~*α*~13~*β*~20~*α*~14~ ([@b0315]).

However, domain 1 is responsible for glycerol binding and domain II is for ADP binding. The adenine base of ADP slipped into a pocket of domain II and the ribose-phosphate functionality pointed towards the interdomain cleft. The nucleoside (adenine-sugar) shows typical, kinase domain triad interactions (*H*-bond acceptor/donor/acceptor interactions ([@b0270])) with kinase domain (Asn418, Ser332 and Gly313) of *Pf*GK. The phosphate binding pocket surrounded by Gly267, Thr268, Gly413 and Gly414 are profoundly required in the ternary closed complex with ATP. While, sugar binding pocket constituted by residues like Gly313, Ser314 and Met415 ([@b0160]; [@b0315]), see in [Fig. 7](#f0035){ref-type="fig"}(A).Fig. 7Interactive mode (A) co-crystallise ADP (gold); (B) *R*-Cassiarin D (purple); (C) *S*-isomer of Cassiarin-D (green); (D) *R*-Cassiarin-E (pink).

The phenolic (*O*H) and propanone functionalities of 5-propenone-7-hydroxy-4*H*-chromen-4-one of *R*-Cassiarin-D utilises triad interaction like adenine, with backbone of Asn418 (2.35 Å) and side chain of Ser332 (2.26 Å), as shown in [Fig. 7](#f0035){ref-type="fig"}(B). Although, *S*-isomer of Cassiarin-D also interacted with Asn418 (2.15 Å) in a similar fashion like *R*-isomer, but as because *C*~2~ stereochemistry changes in both isomer, the remaining halves of both isomers oriented differently, as *R*-isomer extended towards Leu320, over Thr268 while *S*-isomers twisted in L-shaped into the vicinity of Thr268, shown in [Fig. 7](#f0035){ref-type="fig"}(C). However, the presence of Pro328 and Met415 parallel to the *C*~2~ tethered backbone in both stereoisomers binding conformations, showed their utilisation of sugar binding region. Also, *R*-Cassiarin-E follows the same trend as like Cassiarin-D isomers binding with kinase region, as its phenolic O*H* involved in *H*-bond donor interactions with backbone of Asn418 (2.17 Å). However, *R*-Cassiarin-E doesn't have 5-propenone-7-hydroxy-4*H*-chromen-4-one functionality like Cassiarin-D isomers, but has *bis*-tricyclic system, which encloses most of the Cassiarin-D isomers binding cavity residues, [Fig. 7](#f0035){ref-type="fig"}(D).

3.6. Plasmodium falciparum Arginase (PfAI) {#s0065}
------------------------------------------

*Pf*AI (PDB: 3MMR, *Res.* 2.14 Å, ([@b0115])) has close resemblance with its human homologous proteins, human arginases I (*Hs*AI, 28%) and II (*Hs*AII, 27%) and also utilises binuclear manganese ([@b0250]). The interactive mode of co-crystallise ligand (2(*S*)-amino-6-boronohexanoic acid, ABH) of the *Pf*AI illustrated the key important residues of the active site, as it has *H*-bond interactions with Glu368, Asp274, Ser229, Asn222 and forms tetrahedral geometry with both the manganese atoms ([@b0355]; [@b0115]), see in [Fig. 8](#f0040){ref-type="fig"}(A).Fig. 8Interactive binding mode: (A) co-crystallise ABH (gold); (B) R-Cassiarin-C (blue); (C) S-Cassiarin-C (violet); (D) S-DHB (brown).

The molecular docking of these Cassiarins shows their utilisation of the ABH binding cavity. Whereas, the *R*/*S* isomer of Cassiarin-C flipped their orientations, displaying the influence of their *C*~2~ stereochemistry and relatively small molecular size with regards to the cavity size, shown in [Fig. 8](#f0040){ref-type="fig"}(B) and (C), respectively. Their flipping in orientation can be further understood based on their interactions as the phenolic (O*H*) and *O-*pyran ring of *R*-Cassiarin-C has *H*-bond acceptor interactions with His218 (2.77 Å) and Thr337 (2.80 Å) while, the phenolic (O*H*) of *S-*Cassiarin-C has *H*-bond donor interactions with Asp274 (2.24 Å) and Glu277 (2.57 Å) and its *O-*pyran ring has *H*-bond acceptor with Asn222 (2.44 Å). On the other side, the *S*-DHB shows *H*-bond acceptor interactions with side chain of Ser229 (2.99 Å) and Asn222 (2.08 Å), as shown in [Fig. 8](#f0040){ref-type="fig"}(D). These isoforms binding utilises only one manganese metal ion for coordination in their 4.5 Å, which is irrespective to the conventional inhibitors as their binding utilises two manganese atoms. This point could be useful in developing a hepatic antimalarial drug in future, as *Pf*AI has been critical for malarial parasites during their liver stage development.

3.7. Nucleosome assembly protein {#s0070}
--------------------------------

*P. falciparum* contains two nucleosome assembly proteins termed *Pf*NapL and *Pf*NapS ([@b0050]). *Pf*NapL (PDB: 3FS3, *Res.* 2.3 Å, ([@b0140])) is a 347-amino acid dimer, cytoplasmic localised protein and has a central core of ∼250 residues that are thought to be responsible for histone binding. *Pf*Nap composed of two domains, domain-I (consists, dimerization helix-2, region started from 37 to 87) and domain-II, containing multiple *α*-helices and a subdomain containing four antiparallel *β*-strands (amino acid residues 128--185) ([@b0140]). The dimerization helix-2 of domain-I forms the distinguishing shape of *Pf*NapL, where two backbone helices cluster in an antiparallel manner to form the dimer using mainly hydrophobic interactions and salt bridges or hydrogen bonds ([@b0140]).

The *R*-Cassiarin-E binds in a V-shaped, as shown in [Fig. 9](#f0045){ref-type="fig"}(A), where both aromatic cores go inside to the cavity composed of *α*~2~ (Arg68, His72 and Tyr 75) of dimerization helix-2, *α*7 (Tyr272, Pro271, Lys266 are the residues involved), Gly145 and Phe146 at the tip of *β*~2~, and Met169, Val179 are in the loop in between *β*~3~ and *β*~4~, and exposes its CH~2~-tethered backbone to the surface, as seen in [Fig. 9](#f0045){ref-type="fig"}(A). Whereas, its *O*-dihyropyran ring and phenolic *O*H interacts with N*H~2~* terminus of Lys266 (3.20 Å) and N*H*-imidazole side chain of His72 (2.28 Å), respectively. While, in case of *S*-DHB, the pyran ring faces towards Cys133, Tyr79, encloses into a cavity composed of Lys266, Glu267, Ile270 and Pro271 on one side and Arg68, His72 and Tyr135 from other side (see, in [Fig. 9](#f0045){ref-type="fig"}(B)).Fig. 9Interactive binding mode: (A) *R*-Cassiarin-E (pink); (B) *S*-DHB (brown).

3.8. Adenylosuccinate synthetase (PfAdSS) {#s0075}
-----------------------------------------

Each subunit of *Pf*AdSS (PDB: 1P9B, *Res*. 2.0 Å ([@b0120])) consists of 19 strands (*β*~1~-*β*~19~), 12 *α*-helices, seven 3~10~ helices and 6 loops (L~1-5~). Nine parallel *β*-strands (*β*~9~, *β*~7~, *β*~5~, *β*~2~, *β*~10~, *β*~1~, *β*~11~, *β*~15~ and *β*~18~) along with a tenth antiparallel strand (*β*~19~) forms a central sheet. This sheet is bordered by four subdomains: (a) subdomain-I (residues 54--65) comprises of only two *β*-strands (*β*~3~ and *β*~4~); (b) subdomain-II (residues 114--206) mainly involved in interface interactions; (c) subdomains-III (residues 278--302) majorly constitute ligand binding pocket; (d) subdomain-IV (residues 339--418). It has 2 binding sites: orthosteric (IMP binding site) and allosteric (GTP binding site). Both sites are close to each other. The previous studies highlighted various structural features and key residues of active site, as summarised here, ([@b0120]): (a) Lys31 (which is a conserved residue in active site); (b) Lys62 (forms *H*-bonds with ribose hydroxyls in *Pf*AdSS but absent in the other homologous AdSS proteins); (c) Lys29 is highly involved in phosphate head binding of GDP and shares a typical *H*-Bond character (Low Barrier Hydrogen Bond, LBHB, ([@b0075])); (d) phosphate binding pocket majorly constituted by the residues, like Asp26, Lys29, Gly53, His54 and Asn232; (e) Asp26 is believed to be a key residue which gets protonated and later coordinated to Mg^2+^ ([@b0055]; [@b0165]). (f) Asn232, which interacts with IMP, similarly present in the *E. coli* and mouse AdSS complexes, (g) LBHB interaction of His54 and O~2~ of 6-phosphoryl of IMP (2.54 Å), is parallel to the mouse synthetase complex (2.46 Å) ([@b0075]; [@b0165]).

The molecular docking of *R*-DHB shows, its pyran ring utilise the N*H*-guanidine side chain of Arg313 of *β*~13~ (2.16 Å & 2.30 Å) and alcoholic (O*H*) side chain of Thr307 of most conserved segment of loop L~5~ (2.62 Å) *via* H-bond acceptor interactions, see in [Fig. 10](#f0050){ref-type="fig"}(A). However, its binding pocket shows conserved helix *α*~1~(G^28^L^29^G^30^K^31^), L~5~ region containing {(H^303^Y^305^T^307^), *β*~13~ (R^313^) and L~6~ (P^428^) of the *Pf*AdSS. However, *S*-DHB also shows similar binding like R-DHB to the pocket, like *α*~1~(L^29^G^30^K^31^), *β*~3~ (H^54^), L~5~ (E^304^T^307^), *β*~13~(R^313^). While, its quinone ring and 2*H*-pyran ring has *H*-bond acceptor interaction with N*H* of backbone of Gly30 (2.15 Å) and N*H* side chain terminus of Lys339 (2.44 Å), as seen in [Fig. 10](#f0050){ref-type="fig"}(B).Fig. 10Interactive mode: (A) R-DHB (cyan); (B) S-DHB (brown).

3.9. Glucose-6-Phosphate isomerase (PfG6PI) {#s0080}
-------------------------------------------

As no further structural information for *Pf*G6PI protein (PDB: [3PR3](pdb:3PR3){#ir005}, *Res*. 2.45 Å, ([@b0135])) was available, hence we evaluated its own co-crystallise ligand (fructose-6-phosphate) binding, to allocate the key residues in its active site. The binding shows its phosphate head has *H*-bond network with Ser159, Ser231, Lys232, Thr233 and Thr236, while polar heads of fructose sugar has *H*-bond interaction with Gly158, Glu380 and Lys540, see in [Fig. 11](#f0055){ref-type="fig"}(A). Furthermore, compared with human protein (*Hs*G6PI, PDB:1JLH, *Res.* 2.1 Å ([@b0080])), *Pf*-G6PI found to have two globular domains (as one, large and other, small domains) and an "arm-like" *C*-terminal tail, similar like *Hs*G6PI of humans. Both the large and the small domain have a central core of a *β*-pleated sheet flanked by *α*-helices to form a typical *α*/*β* folding motif. The large domain contains 6 *β*-strands (*β*~1~:^40^I to ^42^K; *β*~2~: ^46^F to ^52^R; *β*~7~:^357^N to ^362^P; *β*~8~:^400^V to ^402^F; *β*~9~:^425^V to ^430^F; *β*~10~: ^495^S to ^500^F) and small domain has 4 *β*-strands (*β*~3~: ^150^N to ^154^I, *β*~4~: ^201^N to ^205^L; *β*~5~: ^225^T to ^230^I; *β*~6~: ^264^M to ^267^V).Fig. 11(A) co-crystallise fructose-6-phoaphate (gold); (B) *R*-DHB (cyan); (C) *R*-Cassiarin-D (purple).

The molecular docking of *R*-DHB shows its binding complimentary to the fructose-6-phosphate as the presence of residue 156--159 and 231--239 shows the phosphate binding pocket of fructose-6-phosphate, which is situated in between *β*~3/4~ and *β*~5/6~, respectively, as shown in [Fig. 11](#f0055){ref-type="fig"}(B). While, *R*-Cassiarin-D shows similar binding orientation to the cavity, situated in *β*~5/6~: Lys232, Thr233, Thr236, flanked *α*-helix (Gly293, Arg294), *β*~7/8~ (Gln376, Glu380), *C*-terminal tail (Lys540) and enclosed within *H*-bond distance with charged side chains of Glu380 (2.09 Å), Arg294 (2.33 Å) and backbone of Gly293 (2.92 Å), shown in [Fig. 11](#f0055){ref-type="fig"}(C).

3.10. Kelch motif associated protein of Plasmodium falciparum (PfKEAP) {#s0085}
----------------------------------------------------------------------

It is BTB domain containing 389 residues long dimer (PDB: 4YY8, *Res.* 1.81 Å, ([@b0175]), constituted by 28 *β-*strands where *β*~4~ to *β*~28~ involved in the formation of its 6 kelch motifs: Every motif contains 4 *β*-strands in common, except motif 5, which has unusual 6 *β* strands (***K~1~***: *β~4~*^L444-I448^, *β~5~*^460-464^, *β~6~*^469-472^, *β~29~*^Ser720-Ala724^; ***K~2~*** *β~7~*^484-489^, *β~8~*^491-495^, *β~9~*^508-512^, *β~10~*^517-520^; ***K~3~*** *β~11~*^532-536^, *β~12~*^539-543^, *β~13~*^555-559^, *β~14~*^564-567^; ***K~4~*** *β~15~*^579-583^, *β~16~*^586-590^, *β*~17~^601-605^, *β*~18~^610-613^; ***K~5~*** *β~19~*^622-624^ *β~20~*^627-630^, *β~21~*^633-637^, *β~22~*^640-642^, *β~23~*^650-654^, *β~24~*^659-663^; ***K~6~*** *β~25~*^674-678^, *β~26~*^682-685^, *β~27~*^696-700^, *β~28~*^705-709^). These 6 kelch motifs together built a propeller architecture, shown in [Fig. 12](#f0060){ref-type="fig"}(B). Further comparative sequence and structure studies with human (*Hs*KEAP, PDB: [4XMB](pdb:4XMB){#ir010}, Res. 2.43 Å) ([@b0170]) and mouse (*Mm*KEAP, PDB: [4ZY3](pdb:4ZY3){#ir015}, Res. 1.80 Å) ([@b0310]) kelch motif containing proteins, show key residues associated with the orthosteric binding site, [Fig. 12](#f0060){ref-type="fig"}(A).Fig. 12(A) Multiple sequence alignment (MSA) with human (*Hs*KEAP1) and mouse (*Mm*KEAP1) kelch proteins; (B) Superpose of human (yellow) and *P. falciparum* (brown) kelch protein; (C) Human kelch protein co-crystallise ligand (brown) utilising the similar cavity of *P. falciparum* kelch protein (yellow).

The co-crystallise ligand (mono-alkylated *p-*substituted sulphonamides) of *Hs*KEAP1 fits in between cavity surrounded by kelch repeats *K*~3/4/5~: F^451^Y^456^Y^482^N^498^R^529^ N^530^Y^546^I^551^S^576^S^577^T^593^G^595^E^596^R^597^S^623^S^624^ of *Pf*KEAP, shown in [Fig. 12](#f0060){ref-type="fig"}(C). The cross docking of co-crystallise ligand of *hs*KEAP1 on *Pf*KEAP, shows distinctive kelch motif features in *Pf*KEAP as compare to the kelch motifs of human proteins, as further supported by minimum RMSD value (4.84 Å) and free energy (−7.86) for *Pf*KEAP than minimum RMSD (1.07 Å) and free energy (−7.34) for *Hs*KEAP. While in our observation, we found *R*-Cassiarin-E (−15.2877) and *S-*Cassiarin-C (−12.22) are more profoundly forming energy-stable complexes with *Pf*KEAP. Also, their interactive mode has similar binding pattern as --OH groups of *R*-Cassiarin-E interacts with the backbone of ***K~2~*** region through *H*-bond acceptor-donor interactions, as shown in [Fig. 13](#f0065){ref-type="fig"}(A). While, the other half, fits in the hydrophobic cavity constituted by aromatic amino acids. On the other side, the *S-*Cassiarin-C uses multi kelch motifs as compared to *R*-Cassiarin-E (***K*~2~** (*β*~7~), ***K*~4~**(*β*~15~), ***K*~5~** (*β*~19~ *β*~20~), ***K*~6~**(*β*~25~), ***K*~1~**(*β*~29~)), for its binding to *Pf*KEAP *via H*-bond acceptor/donor interaction with Ser720 (2.67 Å) and Phe674 (2.41 Å) respectively, as shown in [Fig. 13](#f0065){ref-type="fig"}(B).Fig. 13(A) MSA of *Pf*OAT with *Ts*OAT and *Hs*OAT. (B) Interactive domain of *S-*Cassiarin-E (yellow).

3.11. Ornithine δ-aminotransferase of Plasmodium falciparum (PfOAT) {#s0090}
-------------------------------------------------------------------

*Pf*OAT (PDB:[3LG0](pdb:3LG0){#ir020}, *Res.* 2.3 Å, ([@b0180])) is active as a homodimer. Based on the comparative sequence alignment with other OATS (Human: *Hs*OAT, PDB: [2OAT](pdb:2OAT){#ir025}, *Res.* 1.95 Å ([@b0340]); Toxoplasma: *Ts*OAT, PDB: [5E3K](pdb:5E3K){#ir030}, *Res*. 1.73 Å ([@b0125])) (shown in [Fig. 14](#f0070){ref-type="fig"}(A)), we observed high percentage of conserved residues in the active cavity, which is close to the interface of two subunits. Each subunit contains a pyridoxal-phosphate (PLP) binding domain and a substrate binding domain ([@b0180]). The PLP binding loop domain (region started from 287 to 293) is strictly conserved in all species. The *S-*Cassiarin-E binds significantly with the PLP-binding loop domain *via H*-bond donor interaction with amide backbone of Pro286 (2.13 Å) and His289 (2.23 Å); *π* stacking interaction with imidazole ring of His289 (4.24 Å). Furthermore, *N*~1~-isoquinoline (2*H*) has *H*-bond acceptor interaction with N*H*-guanidine side chain of Arg83 (2.10 Å). While the 2*H*-isoquinoline ring folded towards a hydrophobic cavity (comprises V^106^L^107^M^108^M^109^) which allows the Cassiarin-E to undergo the specific binding conformation, shown in [Fig. 14](#f0070){ref-type="fig"}(B).Fig. 14Interactive binding mode: (A) *R*-Cassiarin-E (pink); (B) *S*-Cassiarin-C (violet).

3.12. Enoyl acyl carrier protein reductase (PfENR) {#s0095}
--------------------------------------------------

Previous studies on the protein, enoyl acyl carrier protein reductase obtained from different origins (*P. falciparum*, *E. coli*, *B. napus*, *M. tuberculosis*, *H. pylori*) show overall identical structural homology ([@b0300]). This analysis also provides the key features, related to the substrate binding loop region, which were further correlated with the affinities of its conventional inhibitor class, Triclosan derivatives ([@b0010]). The Triclosan derivatives are primarily contain the Biphenyl ether scaffold (Ring A and Ring B separated by an oxygen atom). In case of *Pf*ENR, the binding of Triclosan (PDB: [3LT0](pdb:3LT0){#ir035}, *Res.* 1.96 Å, ([@b0235])) typically forms a ternary complex as *Pf*ENR-NAD^+^-Triclosan, where ring A of Triclosan settles into a hydrophobic pocket (composed of Tyr277, Tyr267, Gly313, Pro314, Ile323, Phe368, Ile369, and Ala372) and has *π*-stacking interaction distance with nicotinamide ring of the cofactor NAD^+^ ([@b0235]), in [Fig. 15](#f0075){ref-type="fig"}(A). While, Ring B of triclosan has close proximity with ribose-phosphate functionalities of NAD^+^, substrate-binding loop residues (like Ala319, Ala320, and Ile323) and a conserved loop (containing Ala217, Asn218, Ala219, and Val222) ([@b0300]).Fig. 15Interactive binding mode (A) co-crystallise ligand (gold); (B) *R*-Cassiarin-E (pink).

The molecular modelling of Cassiarin-E advocates the binding to the co-factor binding site irrespective to the expected substrate binding site. The tricyclic ring of *R*-Cassiarin-E forms the sandwich-type *π*-*π* interactions with indoyl moiety of Trp131 (3.82 Å, 4.08 Å, 4.58 Å, 3.73 Å, 3.89 Å & 4.29 Å). While, the remaining part of the molecule twisted towards the ribose-phosphate sugar pocket of NADH, which was also a binding pocket of Ring B of Triclosan, see in [Fig. 15](#f0075){ref-type="fig"}(A). This tricyclic ring of this twisted half also has *H*-bond donor/acceptor interaction with Asp107 (2.34 Å) and N*H* backbone of Ala217 (2.90 Å) of cavity domains (comprising G^106^D^107^N^109^G^110^ and S^317^R^318^A^319^) on one side and A^217^N^218^ on other side, respectively, as shown in [Fig. 15](#f0075){ref-type="fig"}(B).

3.13. Oxoacyl acyl-carrier-protein reductase (FabG) {#s0100}
---------------------------------------------------

Most of the interactive domain information for 3-oxoacyl acyl-carrier-protein reductase (PDB:[2C07](pdb:2C07){#ir040}, *Res.* 1.50 Å, ([@b0380])) was limited to Triclosan orthosteric site inhibition, while co-factor binding was highly underestimated. Therefore, we explore the co-factor binding site (NADPH binding site) with 3-oxoacyl acyl-carrier-protein reductase of *E. coli* (PDB: [1Q7B](pdb:1Q7B){#ir045}, *Res.* 2.05 Å, ([@b0305])), found RMSD of their backbone (1.455 Å, for 237 amino acids), identity (47.1%) and similarity (68.0%) and with 4 key mutations, as indicated, in [Fig. 16](#f0080){ref-type="fig"}(A): Ser99 (Gly41 in *E. coli*), Ser94 (Ala36 in *E. coli*), Arg95 (Thr37 in *E. coli*) and Ser198 (Gly137 in *E. coli*). The molecular modelling studies revealed the binding of *R*-isomer of Cassiarin-E, majorly utilises the binding cavity of nicotinamide functionality of NADP, in [Fig. 16](#f0080){ref-type="fig"}(B). However, its *H*-bond donor/acceptor interaction with backbone (--N*H*) of Ser98 (2.68 Å) and phenolic (O*H*) of Tyr212 (2.01 Å) side chain, evident its binding to the phosphate binding cavity of NADP. The tricyclic aromatic ring of R-Cassiarin-E has T-shaped *π*-*π* interaction of Phe244 (3.55 Å & 3.79 Å) ([@b0335]), as shown in [Fig. 16](#f0080){ref-type="fig"}(B).Fig. 16(A) Superpose of FabG protein of *P. falciparum* (residues labelled in brown) with *E. coli* utilising identical ligand (triclosan derivative) binding orthosteric site; (B) Interactive mode of *R*-isomer of Cassiarin-E.

3.14. Armadillo repeats only protein of Plasmodium falciparum (PfARO) {#s0105}
---------------------------------------------------------------------

*Pf*ARO is poor studied protein (PDB: [5EWP](pdb:5EWP){#ir050}, *Res.*1.8 Å ([@b0295]; [@b0030])), therefore we compare its structure with the truncated structure of cell adhesion protein of *Caenorhabditis elegans* (PDB:[4R11](pdb:4R11){#ir055}, *Res.* 2.79 Å) ([@b0065]), see in [Fig. 17](#f0085){ref-type="fig"}(A)*.* Our investigation found PfARO is 252 amino acid residues long, right handed super helix dimer of 15 *α*-helixes, which forms a characteristic alpha solenoid structure ([@b0295]). However, each Armadillo repeat is composed of a pair of alpha helices that form a hairpin structure (involving alpha-helixes: *α*~1~^37-48^, *α*~2~^51-57^, *α*~3~^81-93^, *α*~4~^100-107^, *α*~5~^110-118^, *α*~6~^123-136^, *α*~7~^141-149^, *α*~8~^153-159^, *α*~9~^165-179^, *α*~10~^183-191^, *α*~11~^194-200^, *α*~12~^215-228^, *α*~13~^236-243^, *α*~14~^247-254^, *α*~15~^260-273^; β-strands: *β*~1~^229-230^ and *β*~2~^233-234^). The molecular docking of *S-*Cassiarin-D isomer shows its binding dependent on the turn, as enclosed by the interface of *α*~2/3~ region (containing A^67^A^70^H^72^P^73^W^74^A^75^A^76^D^77^). Also, its O*H* group shows *H*-bond donor interaction with His72 (2.57 Å) and Asp77 (2.02 Å) with the mentioned interface of *α*~2/3~ region, in [Fig. 17](#f0085){ref-type="fig"}(B).Fig. 17(A) Superpose with cell adhesion protein of *Caenorhabditis elegans* (grey colour backbone); (B) Interactive mode of *S*-Cassiarin D (green).

3.15. Methionine aminopeptidase 1b (pfMetAP) {#s0110}
--------------------------------------------

As no structural information related to the *pf*MetAP (PDB: [3S6B](pdb:3S6B){#ir060}, *Res.* 1.95 Å, ([@b0365], [@b0370])) was disclosed by the previous studies, therefore we performed comparative studies of its structure with its human homologous protein (*Hs*MetAP, PDB: [2G6P](pdb:2G6P){#ir065}, *Res*. 1.9 Å, human methionine aminopeptidase Type 1) ([@b0150]). The superimposition of *pf*MetAP and *Hs*MetAP shows the coverage of 81%, RMSD of their backbone (1.253 Å, for 301 amino acids) and identity (54%), as structures shown in [Fig. 18](#f0090){ref-type="fig"}(A). Although, the binding of co-crystallise ligand with *pf*MetAP, shows high resemblance in their orthosteric site, with subtle mutation that could be exploited for selective drug designing and targeting against *P. falciparum* in future, as follow: Thr156 and Ser268 mutated in place of Pro192 and Cys301 (in human), respectively provide *H*-bond donor/acceptor interaction, see in [Fig. 18](#f0090){ref-type="fig"}(A). However, the tricyclic ring of *R*-DHB binds in the hydrophobic core (containing T^156^Y^159^F^162^C^167^H^176^ & H^270^F^276^H^277^ W^320^) and its quinone functionality secured the polar interface of *pf*MetAP constituted by D^193^D^204^E^303^E^334^ (see in [Fig. 18](#f0090){ref-type="fig"}(B)).Fig. 18(A) Comparison of orthosteric site of *pf*MetAP (residues with brown backbone) and *Hs*MetAP (residues with grey backbone) show complimentary evolutionary mutations at Thr156, Ser268; (B) Binding mode of *R*-DHB with *pf*MetAP: utilises the major residues and shows tricyclic core spatially coplanar oriented over Phe276.

3.16. Guanosine monophosphate synthetase (GMP synthetase) {#s0115}
---------------------------------------------------------

GMP synthetase (PDB: [3UOW](pdb:3UOW){#ir070}, *Res*. 2.72 Å, ([@b0365], [@b0370])) is dimeric in nature. Each monomer is composed of two catalytic domains, an *N*-terminal independent GATase (1--236) and a *C*-terminal ATPPase domain (237--555) ([@b0005]). Its dimer form is highly required for its activity as the interface has 108*C*-terminal residues of the ATPPase domain. In this interface, two *cis*-prolines (Pro548--Pro549) allow a tetrahedral configuration of Asp543, Thr551, Glu553 and Arg539 ([@b0005]). The binding of co-crystallise xanthose monophosphate (XMP) ([@b0135]) shows the key residues of ligand binding site of *GMP synthetase*, shown in [Fig. 19](#f0095){ref-type="fig"}(A): (a) Arg336, Pro436, Gly435, Pro436 covering the purine face of XMP; (b) the steric hindrance of bulky hydrophobic residues Phe510, Pro432 twisted the ribose sugar towards the polarised domain (constituted by Arg441, Gln476); (c) phosphate heads enclosed by the Lys547, Glu553, Thr551 and Ile552. However, binding of tricyclic ring of *R*-Cassiarin-E fitted to the purine-ribose sugar binding cavity (*π*-*π* interactions, 3.69 Å & 3.48 Å with Phe510) while the methylene (--CH~2~--) tethered substructure of the molecule (Dihydro-isoquinoline) popped out from the XMP binding cavity, see in [Fig. 19](#f0095){ref-type="fig"}(B).Fig. 19Interactive binding mode (A) XMP (gold); (B) *R*-Cassiarin-E (pink), with guanosine monophosphate synthetase.

3.17. Merozoite surface proteins duffy binding like Domain-2 (PfMSPDBL2) {#s0120}
------------------------------------------------------------------------

The merozoite surface proteins of *P. falciparum* has duffy binding like domains (*Pf*MSPDBL1 and *Pf*MSPDBL2), which helps the merozoite for their initial binding to the surface receptors on the host red blood cell ([@b0375]). The duffy binding like (DBL) fold (PfMSPDBL2; PDB: [3VUU](pdb:3VUU){#ir075}, *Res.* 2.09 Å, ([@b0145])) consists of residues from 161 to 457 residues, which has a boomerang shaped *α*-helical core (9 *α*-helixes) formed from three subdomains ([@b0145]): (a) subdomain-1 (region 161--225) has only contain 5 residue long *α*-helix (*α*~1~) and provide a stable junction for subdomain-2 and subdomain-3 by a *H*-bond network (involving Arg-207 (from subdomain 1), Asp-266 (from subdomain-2), and Glu-352 (subdomain-3)); (b) Subdomain-2 (residues 226--341) composed of four structurally conserved helices (helices 2--5); (c) subdomain-3 (344--460) is a helical bundle composed of two long *α*-helices (*α*~6~ and *α*~7~) and two smaller *α*-helices (*α*~8~ and *α*~9~) ([@b0145]). Moreover, a disulfide linkage between Cys441 and Cys444 brings helices *α*~8~ and *α*~9~ are near each other in an anti-parallel manner. The *R*-Cassiarin-D molecular binding mode clearly shows no involvement with subdomain-1 and binds inside the cavity formed by subdomain-2 and subdomain-3: N^252^E^254^K^255^R^261^ of *α*~3~, T^335^G^336^Y^337^G^338^I^340^D^443^ are in end-tip between helix *α*~5/6~, R^351^T^355^E^359^ in *α*~6~; P^442^E^443^C^444^K^445^ in loop between *α*~8/9~. Also shows, the *H*-bond donor-acceptor interactions with COOH of Glu443(2.97 Å) and N*H*~2~ terminal of Lys445(2.69 Å), see in [Fig. 20](#f0100){ref-type="fig"}.Fig. 20Interactive binding pose of *R*-Cassiarin-D (purple) with *Pf*MSPDBL2.

In our interest, we evaluated the physicochemical properties of these isoforms with regards to the known quinine alkaloid analogues (Chloroquine, Primaquine, Amodiaquine, Mefloquine). However, most of the Cassiarins show equivalent physicochemical properties with respect to the quinine analogous, while Cassiarin-C found to be the closest candidate with Primaquine, as shown in [Table 6](#t0030){ref-type="table"}.Table 6Physiochemical evaluation of various isoforms along with the quinine alkaloids.Moleculea_acca_dona_don_acca_aro*log*P~(o/w)~*log*SMol_wtChloroquine213104.28−3.78319.8Primaquine325102.21−2.24259.3Amodiaquine325164.57−4.49355.8Mefloquine325104.27−4.53378.3Cassiarin-A213102.18−3.18213.2Cassiarin B20202.90−4.04313.3Cassiarin B (R~2~ = Phenyl)10164.22−5.25289.3Cassiarin C314102.24−2.67215.2Cassiarin D628163.40−5.75445.4Cassiarin E527204.15−6.13426.4Cassiarin F538224.84−7.45427.4Cassiarin G516102.30−3.13259.2Cassiarin H50502.59−3.88359.3Cassiarin J628102.10−2.89333.3Cassiarin K213102.85−4.01247.6DHB20202.12−3.18216.2[^15]

4. Conclusion {#s0125}
=============

The search for new antimalarial scaffold still have valuable weightage. Current research identified the most putative targets for Cassiarin alkaloids in *P. falciparum*. We also produce a series of top 25 putative targets for individual Cassiarin isoforms against *P. falciparum* (provided in [Supplementary information](#s0140){ref-type="sec"}). Also, found that the monomer forms (like Cassiarins C and DHB) have comparatively more cavity fitting to these proteins, as attributed by their smaller surface area than their *Bis*-forms (D, E, and F) (provided in [Table 2](#t0010){ref-type="table"}). However, their multi-mode interactions with their putative protein targets also indicate their synergistic pharmacological mode of action against *P. falciparum* strains. We also disclosed various comparative studies of identified protein targets with their homologous proteins, especially human homologous proteins, which were never studied before and therefore draws several key structural features and differences that could be further exploited in designing and selective targeting against these identified proteins, as provided in case of Oxoacyl acyl-carrier-protein reductase, Kelch motif associated protein, Armadillo repeats only protein and Methionine aminopeptidase 1b. We also found that the screening based on inverse docking, using three different docking methods, quite helpful in filtering the pseudo-positive results which are usually generated from one docking method. This kind of methodology could be useful in, the exploration and target identification for polypharmacological active compounds or validating the side targets of a particular drug.
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[^1]: Both authors have equal contribution.

[^2]: Chloroquine-sensitive *P. falciparum* strain 3D7.

[^3]: *P. falciparum* 3D7.

[^4]: MCF7 (human breast adenocarcinoma) cell line.

[^5]: HL-60 Human blood premyelocytic leukaemia.

[^6]: P388 mouse leukaemia cells.

[^7]: Putative.

[^8]: Both have close self-docking RMSD.

[^9]: Pairwise Sequence alignment shows PF3D7_0823300 (GCN5) ¥ is a Histone acetyltransferase (GCN5).

[^10]: It is isoform-3 of Falcipain and has identity of ∼66%.

[^11]: co-crystallise ligand is in racemic mixture.

[^12]: Na: no co-crystal ligand. Res. = Resolution of crystal structure.

[^13]: Total Energy ~(MM2)~ = E*~Str~* + E*~B~* + E*~Str-B~* + E*~tor~* + E*~nVDW~* + E*~VDW~* + E*~d-d~*.

[^14]: *n.a.* no crystallise protein.

[^15]: a_acc: number of *H*-bond acceptor atoms; a_don: number of *H*-bond donor atoms; a_don_acc: number of *H*-bond acceptor + donor atoms; a_aro: number of aromatic atoms; *log*P~(o/w)~: Log water/octanol partition coefficient; *log*S: log solubility in water; mol_wt: molecular weight of molecule.
